TY - JOUR
T1 - The impact of casirivimab-imdevimab antibody cocktail in patients amidst and post COVID 19 treatment
T2 - A retro-prospective comparative study in India
AU - Joy, Aneesh Puthiyedath
AU - Augustine, Anitha Theresa
AU - Karattuthodi, Mohammed Salim
AU - Parambil, Jaffer Chalil
AU - Chandrasekher, Dilip
AU - Danisha, P.
AU - Panakkal, Linu Mohan
AU - Joshi, Madhav A.
AU - Azharul Haque, K. T.
AU - Mohammed Izudheen, Irshad K.
AU - Badaruddeen, Shadia
AU - John, Riya Sara
AU - Murali, Sarath
AU - Thomas, Ardhra Rose
AU - Sahla, Fathimath
AU - Ahmed Unni, Shahir Ahmed KV
AU - Ahmed, Raseel Omar
AU - Cholamugath, Shinu
N1 - Funding Information:
In this section, you can acknowledge any support given which is not covered by the author contribution or funding sections. This may include administrative and technical support, or donations in kind (e.g. materials used for experiments).
Publisher Copyright:
© 2022 The Authors
PY - 2022/3/1
Y1 - 2022/3/1
N2 - Background: Monoclonal antibodies have gained attention in developing countries owing to its benefits portrayed by few clinical trials. However, no studies until now have been undergone in India. Methods: A retro-prospective comparative observational study was conducted in symptomatic COVID19 patients to evaluate the impact of Casirivimab and Imdevimab antibody cocktail in the high-risk population. Through an extensive data retrieval for 6 months, 152 samples were documented and sorted into test (Casirivimab and Imdevimab treated patients, n = 79) and control (Non- Casirivimab and Imdevimab treated individuals, n = 73) subsets. The research had two phases; first, estimation of mechanical ventilation and high flow oxygen requirement and mortality in samples amidst the treatment, and second was the post COVID19 patients' feedback through validated (Cronbach's alpha coefficient = 0.7) questionnaire that evaluated their health and vaccination status, and treatment satisfaction. Results: We noticed lesser requisite for mechanical ventilation (6.3%; p < 0.001), high flow oxygen (5.1%; p < 0.001) and no death during Casirivimab and Imdevimab therapy. Meanwhile, non-vaccinated test groups were not on mechanical ventilation and those fully immunized seldom entailed high flow oxygen (test, 6.3%; control, 41.9%, p < 0.01). On evaluating the post COVID19 status of each patient in the study, 90.1% of the test samples were healthy and 97.2% were satisfied with the treatment than those in control group. Conclusions: Casirivimab and Imdevimab regimen was clinically beneficial for high risk COVID19 patients than those treated without the antibody cocktail.
AB - Background: Monoclonal antibodies have gained attention in developing countries owing to its benefits portrayed by few clinical trials. However, no studies until now have been undergone in India. Methods: A retro-prospective comparative observational study was conducted in symptomatic COVID19 patients to evaluate the impact of Casirivimab and Imdevimab antibody cocktail in the high-risk population. Through an extensive data retrieval for 6 months, 152 samples were documented and sorted into test (Casirivimab and Imdevimab treated patients, n = 79) and control (Non- Casirivimab and Imdevimab treated individuals, n = 73) subsets. The research had two phases; first, estimation of mechanical ventilation and high flow oxygen requirement and mortality in samples amidst the treatment, and second was the post COVID19 patients' feedback through validated (Cronbach's alpha coefficient = 0.7) questionnaire that evaluated their health and vaccination status, and treatment satisfaction. Results: We noticed lesser requisite for mechanical ventilation (6.3%; p < 0.001), high flow oxygen (5.1%; p < 0.001) and no death during Casirivimab and Imdevimab therapy. Meanwhile, non-vaccinated test groups were not on mechanical ventilation and those fully immunized seldom entailed high flow oxygen (test, 6.3%; control, 41.9%, p < 0.01). On evaluating the post COVID19 status of each patient in the study, 90.1% of the test samples were healthy and 97.2% were satisfied with the treatment than those in control group. Conclusions: Casirivimab and Imdevimab regimen was clinically beneficial for high risk COVID19 patients than those treated without the antibody cocktail.
UR - http://www.scopus.com/inward/record.url?scp=85124324651&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85124324651&partnerID=8YFLogxK
U2 - 10.1016/j.cegh.2022.100967
DO - 10.1016/j.cegh.2022.100967
M3 - Article
AN - SCOPUS:85124324651
SN - 2213-3984
VL - 14
JO - Clinical Epidemiology and Global Health
JF - Clinical Epidemiology and Global Health
M1 - 100967
ER -